

04 Dec 2023 | News

Quick Listen: Scrip's Five Must-Know Things

by [Ian Haydock](#)

In this week's podcast edition of Five Must-Know Things: CAR-Ts and malignancies; comeback for GSK's Blenrep?; Novartis's pipeline cull; FGF21 analogs in NASH; and a call to action from the Scrip Awards Lifetime Achievement winner.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 1 December 2023, including: CAR-Ts and malignancies; comeback for [GSK plc's Blenrep?](#); [Novartis AG's](#) pipeline cull; FGF21 analogs in NASH; and a call to action from the *Scrip* Awards Lifetime Achievement winner.

This and all our other podcasts are available on the *Citeline* channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#), [TuneIn](#) and [Spotify Podcasts](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[Risk/Benefit Of CAR-T For Autoimmune Diseases May Shift With FDA Investigation](#)" - Scrip, 29 Nov, 2023.)

(Also see "[Can GSK's Blenrep Make A Comeback After Beating Darzalex? Eye Toxicity Concerns Remain](#)" - Scrip, 27 Nov, 2023.)

(Also see "[Novartis Has A New Goal: \\$2bn Peak Sales Per Product](#)" - Scrip, 28 Nov, 2023.)

(Also see "[Who Will Emerge As Best In Class Of The FGF21 Analogs In NASH?](#)" - Scrip, 29 Nov, 2023.)

SCRIP

CITELINE COMMERCIAL

(Also see "[*Scrip Awards Lifetime Achievement Winner Jeremy Levin Urges Pharma To Put Humanity First*](#)" - Scrip, 24 Nov, 2023.)

[Click here to explore this interactive content online](#) ✨